<2> Extended Follow-up of Invasive Cervical Cancer Risk after Quadrivalent HPV Vaccination: Nationwide, Register Based Study
<3> Background
The quadrivalent human papillomavirus (HPV) vaccine has been widely used to prevent cervical cancer, but the long-term risk of invasive cervical cancer after vaccination remains unclear. A nationwide, register-based study in Sweden evaluated the risk of invasive cervical cancer after receiving the quadrivalent HPV vaccine, how risk varies by time since vaccination, and to assess the population-level impact of HPV vaccination programs.
<4> Methods
This study used a nationwide register-based cohort design with up to 18 years of follow-up. The study included 926,362 girls and women residing in Sweden between 2006 and 2023, born in 1985-88 (opportunistic cohort), 1989-92 (subsidized cohort), 1993-98 (catch-up cohort), or 1999-2001 (school-based cohort), and with no previous HPV vaccination or diagnosis of invasive cervical cancer at the start of follow-up.
<5> Results
During follow-up, 365,502 (39.5%) girls and women received at least one dose of the quadrivalent HPV vaccine.